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INTROduCTION Many surgical and medical in-
patients are at markedly increased risk of ve-
nous thromboembolism (VTE). Such patients 
often have more than one risk factor for VTE, 
and these factors are usually combined. Approx-
imately 5–10% of all deaths in hospitalized pa-
tients are accounted for by pulmonary embo-
lism making VTE the most common prevent-
able cause of in-hospital death.1,2 There are over 
370,000 estimated VTE-related deaths per year 
in 6 European Union (EU) countries; 75% of them 
from hospital-acquired VTE.3 Extrapolation of 
American data indicates that in Poland pulmo-
nary embolism may account annually for up to 
25,000–33,000 deaths.4 Deep vein thrombosis 
and its long-term complications (post-thrombotic 
syndrome, chronic thromboembolic pulmonary 
hypertension) contribute to increased long-term 
patient morbidity and raise the costs for public 
healthcare systems.5,6
Despite the availability of evidence-based con-
sensus guidelines1,7 thromboprophylaxis is often 
not implemented, due to underestimation of the 
risk or variable risk of hemorrhagic complica-
tions related to antithrombotic agents. Several 
epidemiologic studies have addressed the prob-
lem in defined countries and institutions out-
side Poland.8-10 Such studies have not been pub-
lished in Poland yet. 
Until now global data on the proportion of 
at-risk inpatients who should receive thrombo-
prophylaxis have been unavailable. Recently, 
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ObjECTIvEs  The ENDORSE study  in Poland was part of  the global cross-sectional Epidemiologic 
International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute 
Hospital Care Setting survey with the objective to assess the prevalence of VTE risk in acutely ill 
medical and surgical patients and  to determine  the proportion of at-risk patients who  receive  re-
commended prophylaxis.




















For inclusion, each patient had to be hospitalized 
in an eligible ward on the predetermined day of 
survey. In large hospitals it was possible to survey 
one ward or floor on any particular day. 
Patients aged ≥40 years in eligible medical 
wards, or ≥18 years in eligible surgical wards were 
screened. The assessment of VTE risk (according 
to the 2004 ACCP guidelines) included acutely ill 
medical patients, patients hospitalized for ma-
jor trauma or undergoing a major surgical pro-
cedure requiring general or epidural anesthesia 
for at least 45 minutes. Following the 2004 ACCP 
guidelines, surgical patients were classified as be-
ing at highest, high, moderate or low risk for VTE. 
Only information about types of venous throm-
boprophylaxis included in the ACCP guidelines 
recommendations was collected, and only these 
types were taken into account for ACCP compli-
ance determination. Anticoagulant prophylax-
is was considered contraindicated if the patient 
presented with or developed during hospitaliza-
tion any of the following: intracranial hemor-
rhage, liver impairment, bleeding at hospital ad-
mission, an active peptic ulcer, bleeding disor-
ders of a known cause.
statistical analysis Statistical analyses are dis-
cussed in detail in the global primary ENDORSE 
report.11 Briefly, quantitative data were presented 
as median, and the number of non-missing data. 
Categorical data were given as the number and 
percentage of the population. The SAS version 9.1 
was used for all statistical analyses. 
Cohen et al.11 published the results of the multina-
tional, observational, cross-sectional ENDORSE 
(Epidemiologic International Day for the Evalua-
tion of Patients at Risk for Venous Thromboem-
bolism in the Acute Hospital Care Setting) study, 
conducted between August, 2006 and January, 
2007. The study assessed the number of patients 
at risk for VTE in the acute care hospital setting 
in 358 hospitals across 32 countries on 6 conti-
nents and established the proportion of patients 
who received thromboprophylaxis according to 
the recommendations of the American College 
for Chest Physicians (ACCP) guidelines.1 Poland 
took part in this study. This paper presents the 
country-specific data from 10 Polish hospitals 
participating in the ENDORSE study. 
PATIENTs ANd mEThOds Detailed procedures 
have been described in the primary ENDORSE re-
port.11 Briefly, hospitals with >50 beds, admitting 
patients with acute medical illnesses and exacer-
bations of chronic diseases, and scheduled rou-
tine major surgical procedures were included in 
the study. In Poland, 10 non-academic hospitals 
were randomly selected from the Polish Hospital 
Register. According to the national rules, the ap-
proval of the Ethics Committee (Chamber of Phy-
sicians, Kraków) was obtained for the study in Po-
land. Signed patient consent was not required. Pa-
tients’ data, including demographics, admission 
and post-admission diagnoses, risk factors asso-
ciated with VTE, bleeding risk factors for, the du-
ration of a stay and the type of VTE prophylaxis, 
were collected from a review of hospital charts on 
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time to identify and enroll the eligible patients 
was 6 days.
The median age of patients in medical wards 
was 73 years and in surgical wards 62 years. The 
patient’s characteristics and causes of hospital-
ization are shown in TAbLE 1. 
Risk factors for VTE that were present before 
hospital admission are shown in TAbLE 2. Chronic 
heart failure was the most common VTE risk fac-
tor before admission both in medical and surgi-
cal patients (46.3% and 10.3%, respectively). The 
second most frequent VTE risk factor in medical 
patients was chronic pulmonary disease (24.4%) 
and in surgical patients varicose veins/venous 
insufficiency (7.9%). The most common post-
admission risk factor for VTE in both medical 
and surgical patients was complete immobiliza-
tion, followed by immobilization with bathroom 
privileges for surgical patients, and admission to 
an intensive or critical care unit in medical pa-
tients (TAbLE 2).
Risk factors for bleeding were more common in 
medical than surgical patients. This risk in med-
ical patients was mainly due to aspirin use and 
significant impairment of renal function, while 
in surgical patients the bleeding risk was due to 
use of non-steroidal anti-inflammatory drugs 
(TAbLE 3). 
REsuLTs In the global ENDORSE study11, a to-
tal number of 68,183 patients were enrolled from 
358 hospitals across 32 countries (Algeria, Aus-
tralia, Bangladesh, Brazil, Bulgaria, Colombia, 
Czech Republic, Egypt, France, Germany, Greece, 
Hungary, India, Ireland, Kuwait, Mexico, Pakistan, 
Poland, Portugal, Romania, Russia, Saudi Ara-
bia, Slovakia, Spain, Switzerland, Thailand, Tuni-
sia, Turkey, United Arab Emirates, UK, USA, and 
Vene zuela). Out of this number, 30,827 (45%) of 
the eligible patients were categorized as surgical 
and 37,356 (55%) as medical. According to the 
ACCP criteria, 35,329 (51.8%; between country 
range 35.6–72.6) patients were at risk for VTE, 
including 19,842 (64.4%; 44.1–80.2) surgical pa-
tients and 15,487 (41.5%; 21.1–71.2) medical pa-
tients. Of the surgical patients at risk, 11,613 
(58.5%; 0.2–92.1) received ACCP-recommended 
VTE prophylaxis, compared with 6,119 (39.5%; 
3.1–70.4) at-risk medical patients. 
In Poland, a total number of 2,673 patients 
were enrolled from 10 hospitals, 1,092 (40.9%) 
on surgical and 1,581 (59.1%) on medical wards. 
The total number of beds assessed, together with 
reasons for exclusion, and the number of ana-
lyzed medical and surgical patients are shown in 
FIGuRE 1. The  median number of beds per hospi-




Male 289 (49.7) 256 (51.2) 545 (50.4)
Female 292 (50.3) 244 (48.8) 536 (49.6)
Age (years)*   62   73   68
BMI (kg/m2)*   26.1   27.5   26.5
Hospital admission to survey day (days)*     6     7     6
Reason for hospitalization
Acute heart failure (NYHA class III/IV)     8 (1.3) 176 (34.2) 184 (16.6)
Other cardiovascular disease   80 (13.4) 155 (30.2) 235 (21.2)
Ischemic stroke     2 (0.3)   31 (6)   33 (3)
Hemorrhagic stroke     3 (0.5)     6 (1.2)     9 (0.8)
Pulmonary infection     9 (1.5) 186 (36.2) 195 (17.6)
Acute non-infectious respiratory disease     9 (1.5)   93 (18.1) 102 (9.2)
Rheumatologic or inflammatory diseases     6 (1.0)     3 (0.6)     9 (0.8)
Hematologic disease     3 (0.5)   21 (4.1)   24 (2.2)
Malignancy (active)   56 (9.4)   26 (5.1)   82 (7.4)
Infection (non-respiratory)   21 (3.5)   22 (4.3)   43 (4.0)
Neurologic   12 (2)   19 (3.7)   31 (2.8)
Renal   14 (2.3)   45 (8.8)   59 (5.3)
Endocrine/metabolic   39 (6.5)   58 (11.3)   97 (8.7)
Gastro-intestinal/hepatobiliary   65 (10.9)   31 (6)   96 (8.6)





surgical patients, these proportions were 55% 
(Greece) to 78% (France), and 55% (Portugal) to 
92% (Germany), respectively. 
Anticoagulant agents (mainly heparins) were 
used in Poland as the preferred mode of VTE pro-
phylaxis (92.1% of medical patients and 99.2% of 
surgical patients who received the ACCP recom-
mended prophylaxis), followed by antivitamins K 
and other anticoagulants (see TAbLE 4). The use of 
mechanical prophylaxis (foot pump, graduated 
compression stockings, and intermittent pneu-
matic compression) was limited to surgical pa-
tients only (<2% of all prophylactic measures). 
Contraindications to anticoagulant prophy-
laxis were observed in 6.4% of both surgical and 
medical patients. 
dIsCussION The ENDORSE is by far the larg-
est cross-sectional study assessing VTE risk and 
thromboprophylaxis in the acute hospital care set-
ting.11 On a global scale 358 hospitals across 32 
countries completed the study. Out of 340 hos-
pitals which provided characteristic data, 44% 
were categorized as academic. In all hospitals 
participating in the study the number of assess-
able patients approached 70 thousand. About 
50% of them were deemed to be at risk for VTE 
(64.4% of surgical patients and 41.5% of medi-
cal patients). The ACCP-recommended prophy-
laxis was received only by about 50% of patients 
at risk of VTE (58.5% of surgical patients; 39.5% 
Out of 2673 analyzed patients, 1111 (41.6%) 
were deemed as being at VTE risk. Among 1,092 
patients on surgical wards (see FIGuRE 1), 597 
(54.7%) were deemed to be at VTE risk. Four-
hundred four (67.7%) of these at risk patients re-
ceived any VTE prophylaxis and 396 (66.3%) re-
ceived ACCP recommended prophylaxis. Among 
1581 patients on medical wards (see FIGuRE 1), 514 
(32.5%) were deemed to be at risk of VTE. Out of 
these 514 patients, 239 (46.5%) received any VTE 
prophylaxis; 179 (34.8%) received ACCP-recom-
mended prophylaxis. Altogether, in Poland, out of 
1111 inpatients at VTE risk, 575 (51.8%) received 
ACCP-recommended prophylaxis. 
There was a substantial difference between 
participating hospitals in terms of percentages 
of at-risk patients among all analyzed surgical 
(range from 39.3% to 100%) and medical (range 
from 15.5% to 45.6%) patients. Such a marked 
difference was also typical of the everyday prac-
tice of administering ACCP-recommended VTE 
prophylaxis (from 45.2% to 90.8 % for surgical 
patients, and from 8.7% to 55.6% for medical pa-
tients, respectively).
For comparison, the proportion of patients 
at risk for VTE and the use of ACCP-prophylaxis 
in the EU countries are shown in FIGuRE 2. In EU 
countries, the proportion of hospitalized medi-
cal patients at VTE-risk ranged from 31% (Hun-
gary) to 63% (France) and the proportion of pa-
tients receiving ACCP-recommended prophylax-




Previous venous thromboembolism     5 (0.9)   15 (3.0)   20 (1.9)
Thrombophilia (laboratory documented)     1 (0.2)     2 (0.4)     3 (0.3)
Varicose veins or venous insufficiency   42 (7.9)   89 (17.5) 131 (12.6)
Postmenopausal hormone replacement 
therapy
    2 (0.4)     0     2 (0.2)
Chronic pulmonary disease   22 (4.1) 124 (24.4) 146 (14)
Long-term immobility   10 (1.9)   59 (11.6)   69 (6.6)
Pregnancy (within 3 months)     0     0     0
Obese (based on physician's note)   34 (6.4)   85 (16.7) 119 (11.4)
Oral contraceptives     4 (0.7)     1 (0.2)     5 (0.5)
Chronic heart failure   55 (10.3) 235 (46.3) 290 (27.8)
During hospitalization
Admitted to ICU/CCU   20 (3.4)   94 (18.3) 114 (10.3)
Central venous catheter   34 (5.7)   44 (8.6)   78 (7)
Mechanical ventilation   50 (8.4)   27 (5.3)   77 (6.9)
Immobile with bathroom privileges   99 (16.6)   78 (15.2) 177 (15.9)
Complete immobilization 225 (37.7) 142 (27.6) 367 (33.0)
Cancer therapy     0     5 (1)     5 (0.5)
Heparin-induced thrombocytopenia     0     0     0
Data are shown as number (percentage). Denominators may vary due to missing data.
Abbreviations: CCU – critical care unit, ICU – intensive care unit
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 Wide differences in everyday practice of VTE 
prophylaxis in patients deemed as being at risk 
suggest that in many Polish hospitals, despite 
availability of original evidence-based consensus 
guidelines1,7 and its national adaptations13,14, the 
awareness of the risk of VTE in hospitalized pa-
tients is still insufficient. Efforts should be made 
to increase this awareness through vigorous edu-
cational actions and in-hospital alert systems.15 
Heparins were by far the most often used type 
of prophylaxis in Polish medical patients. Me-
chanical prophylaxis was not used. While hep-
arins were even more often used in surgical pa-
tients, a few patients received mechanical pro-
phylaxis, mainly graduated compression stock-
ings. In general, proportions of the type of VTE 
prophylaxis used in Poland are similar to the glob-
al data, but the use of mechanical prophylaxis is 
lower. Similarly to the other European countries, 
8,16 low-molecular-weight heparins (LMWH) were 
the most frequent pharmacologic approach (near-
ly 100% of heparins used) whereas in the USA 
unfractionated heparin was more prevalent in 
this setting.9,10
of medical patients) with substantial variations 
depending on the geographic region.11
In Poland all 10 hospitals participating in the 
study were non-academic to better reflect av-
erage hospital practice. The percentages of pa-
tients at VTE risk receiving recommended pro-
phylaxis were not different from the global data, 
they were however slightly lower than those in 
the neighboring Czech Republic and Slovakia, 
and much lower than in Germany, the leader in 
antithrombotic prophylaxis among all partici-
pating countries.11 Numbers of patients at risk 
were comparable.
This is the first published report on DVT pro-
phylaxis in medical and surgical hospital patients 
in Poland. The only other available in Poland data 
come from the EPID registry.12 This survey per-
formed in internal medicine wards from 64 hos-
pitals has shown that among medical patients at 
VTE risk, 44% received antithrombotic prophylax-
is. This is in agreement with the findings present-
ed in the discussed study (46.5% of all medical pa-
tients at risk receiving any VTE prophylaxis). 
TAbLE 3  Risk factors for bleeding in evaluable patients
Risk factors for bleeding present at current admission Surgical risk (n = 597) Medical risk (n = 514) All risk (n = 1111)
Significant renal insufficiency 16 (2.7)   44 (8.6)   60 (5.4)
Intracranial hemorrhage 18 (3)     4 (0.8)   22 (2)
Low platelet count (<100,000/μl)   6 (1)   16 (3.1)   22 (2)
Known bleeding disorder (congenital or acquired)   2 (0.3)     2 (0.4)     4 (0.4)
Hepatic insufficiency (clinically relevant)   2 (0.3)   12 (2.3)   14 (1.3)
Bleeding at hospital admission 13 (2.2)   10 (1.9)   23 (2.1)
Active gastroduodenal ulcer   5 (0.8)     8 (1.6)   13 (1.2)
Aspirin on admission 19 (3.2) 195 (37.9) 214 (19.3)





Any anticoagulant 399 (67.7) 220 (46.5)   60 (5.4)
Intermittent pneumatic compression  
without anticoagulant
    1 (0.2)     0     1 (0.1)
Graduated compression stockings without 
an anticoagulant or intermittent pneumatic compression
    3 (0.7)     0     3 (0.3)
Low-molecular-weight heparin 392 (65.7) 176 (34.2) 568 (51.1)
Unfractionated heparin   12 (2)     6 (1.2)   18 (1.6)
Vitamin K antagonist     2 (0.3)   31 (6.0)   33 (3)
Fondaparinux     0     0 (0.0)     0
Other anticoagulants     9 (1.5)   23 (4.5)   32 (2.9)
Intermittent pneumatic compression     1 (0.2)     0     1 (0.1)
Foot pump     1 (0.2)     0     1 (0.1)
Graduated compression stockings   11 (1.8)     0   11 (1)
Data are shown as number (percentage). Denominators may vary due to missing data.
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inhabitants and over 700 hospitals, even a ran-
dom choice of ten hospitals might be too low to 
be fully representative. However, the wide vari-
ation of the everyday practice in implementing 
VTE prophylaxis with even the highest numbers 
being far from ideal are a sufficient argument for 
a “call to action”.15 Secondly, some inaccuracies 
might have been introduced during data collec-
tion (one-day cross-sectional study), which how-
ever should not influence general conclusions. 
It is quite probable that the VTE risk factor was 
omitted rather than added in error. Thirdly, VTE 
prophylaxis could have been withheld due to the 
personal conviction of the attending physician 
that the risk of bleeding was high. Finally, sur-
vey awareness could have changed physicians’ be-
havior. Even then, they would probably have in-
creased the use of prophylactic measures rather 
than withhold them.
In summary, results of the ENDORSE study in 
Poland show that, like in many other countries 
all over the world3,8-11,19, VTE prophylaxis is un-
derused in acutely ill medical and surgical inpa-
tients. It seems that especially in medical patients 
the risk of VTE is substantially underestimated. 
Every effort should be made to increase aware-
ness of VTE risk and ensure that at-risk patients 
receive appropriate prophylaxis through obliga-
tory hospital alert systems and implementation 
of evidence-based guidelines. Widespread edu-
cational actions, among other things, could help 
achieve this aim.
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In Poland, as in other countries, including the 
European ones, ACCP-recommended prophylaxis 
was more often used in surgical than in medical 
patients.11 This is probably, at least in part, relat-
ed to the clear VTE risk description for different 
types of surgical procedures included in the 2004 
ACCP recommendations.1 There was no such risk 
categorization for medical patients  in the ACCP 
guidelines. In the recently published 2008 ACCP 
guidelines17 medical patients are categorized into 
2 groups. Fully mobile medical patients are con-
sidered as being of low (<10%) risk of deep-vein 
thrombosis (DVT) and do not require specific 
thromboprophylaxis, in contrast to bedridden or 
acutelyill medical patients who are considered to 
be of moderate (10–40%) risk of DVT. Thrombo-
prophylaxis options for the latter group include 
LMWH, unfractioned heparin or fondaparinux 
administration. Low rates of VTE prophylaxis in 
acutely-ill medical patients at high risk of VTE 
has been described in the past.18
The ENDORSE study on Polish patients has 
several limitations. The first, and the most impor-
tant, is the hospital (and consequently, patients) 






































































































































































LIsT OF ENdORsE INvEsTIGATORs IN POLANd 
(number of the charts surveyed)
1  Wojewódzki Szpital Zespolony, Płock: włodzimierz Klonowski (355)
2  ZOZ im. K. S. Wyszyńskiego, Sieradz: Zdzisław Prajs (279)
3  Regionalny Szpital Chorób Płuc, Szczecin: marek sell (240)
4  Szpital im. J. Dietla, Kraków: Andrzej Kosiniak-Kamysz (235)
5  Radomski Szpital Specjalistyczny, Radom: Tadeusz Kalbarczyk (234)
6   Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych, Olsztyn: 
bartłomiej biedziuk (180)
7  Szpital Wojewódzki, Opole: józef wysota (180)
8  Specjalistyczny Szpital im. E. Szczeklika, Tarnów: marcin Kuta (168)
9   Wojewódzki Szpital Specjalistyczny, Wrocław: wojciech witkiewicz 
(168)
10  Szpital Bielański, Warszawa: Ryszard Gellert (147)
